Centessa Pharmaceuticals plc
NASDAQ:CNTABiotechnology
-$0.07 today
- Market cap
- $6.27B
- Beta
- 1.12
- P/E (TTM)
- -24.4
- EPS (TTM)
- -$1.63
Volume 0.00M
Average 2.63M
CNTA Selling, General & Admin
Overhead costs of running the business, including sales, marketing, management, and administrative staff.
Centessa Pharmaceuticals plcNASDAQ: CNTA
Selling, General & Admin · Q1 FY2026 · quarter ended Mar 2026
Selling, general & admin growth accelerates
Q1 FY2026 selling, general & admin of $19.88M rose 61.2% year over year, ahead of the +16.7% change in trailing-twelve-month selling, general & admin. Sequentially, it rose 42.1% from the prior quarter. Over 3 fiscal years it compounded at -2.9% a year.
Context
- Selling, general & admin amounted to 336.5% of revenue in FY2025.
- Selling, general & admin increased in 0 of the last 3 fiscal years.
- FY2025 was the lowest annual figure in the 4 fiscal years shown.
What to watch
Whether selling, general & admin reaches the consensus estimate from 12 analysts of $8.77M (-82.6%) for the fiscal year ending Dec 2026, a slowdown from the -0.7% reported in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterMar 2026
- $19.88M+42.1% QoQ
- Last fiscal yearDec 2025
- $50.47M-0.7% YoY
- LTMMar 2026
- $58.02M+16.7% YoY
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
Selling, General & Admin history
USD · from the income statement
- Latest · FY2025
- 50.47M USD
- Year-over-year change
- -0.7%
- 4-year CAGR
- +4.1%
| Period | Period end | Selling, General & Admin | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 50.47M | -0.7% |
| FY2024 | 2024-12-31 | 50.81M | -5.4% |
| FY2023 | 2023-12-31 | 53.73M | -2.7% |
| FY2022 | 2022-12-31 | 55.2M | +28.3% |
| FY2021 | 2021-12-31 | 43.01M | — |
Selling, General & Admin vs competitors
How CNTA compares with its peers on the latest reported figures
- Peers report in different currencies, so selling, general & admin is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of +16.7% is the 7th highest of 10, against a peer median of +33.3%.
- Over three fiscal years its annual growth of -2.9% compares with a peer median of +34.4%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
AAPGAscentage Pharma Group International | FY2025 | CN¥522.67M CNY | +36.4% | +16.8% | 93.6% |
| LTM Sep 2026 | $357.49M USD | +10.5% | +25.2% | 26.3% | |
| LTM Mar 2026 | $350.27M USD | +5.7% | +7.9% | 52.3% | |
| LTM Jun 2026 | $281.09M USD | -1.1% | +2.3% | 62.5% | |
| LTM Sep 2026 | $94.24M USD | +24.7% | +34.4% | — | |
| LTM Jun 2026 | $91.25M USD | +50.5% | +35.3% | — | |
| LTM Sep 2026 | $90.71M USD | +34.9% | +125.7% | 1471.2% | |
| LTM Jun 2026 | $83.07M USD | +33.3% | +188.9% | — | |
| LTM Jun 2026 | $71.99M USD | +448.5% | +83.8% | — | |
| LTM Mar 2026 | $58.02M USD | +16.7% | -2.9% | — | |
| Peer median (excluding CNTA) | — | +33.3% | +34.4% | 62.5% | |
Competitors are the stored peer set for CNTA. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 6.85M | 0 | 15M |
| Cost of Revenue | 0 | 0 | 0 | 0 | 0 |
| Gross Profit | 0 | 0 | 6.85M | 0 | 15M |
| Gross Margin | — | — | 100.0% | — | 100.0% |
| Research & Development | 96.32M | 155.08M | 124.41M | 150.24M | 172.22M |
| Selling, General & Admin | 43.01M | 55.2M | 53.73M | 50.81M | 50.47M |
| Operating Expenses | 374.87M | 212.26M | 178.14M | 201.06M | 222.69M |
| Depreciation & Amortization | 34K | 131K | 810K | 942K | 921K |
| EBITDA | (139.3M) | (209.55M) | (165.43M) | (221.88M) | (183.33M) |
| EBITDA Margin | — | — | -2413.9% | — | -1222.2% |
| Operating Income | (374.87M) | (212.26M) | (171.28M) | (201.06M) | (207.69M) |
| Operating Margin | — | — | -2499.4% | — | -1384.6% |
| Interest Income | 0 | 244K | 10.48M | 14.02M | 20.53M |
| Interest Expense | 2.55M | 7.28M | 9.91M | 10.09M | 11.46M |
| Other Income / Expenses | (6.92M) | (4.69M) | (4.86M) | (31.86M) | 11.98M |
| Income Before Tax | (381.79M) | (216.95M) | (176.14M) | (232.91M) | (195.71M) |
| Pre-Tax Margin | — | — | -2570.3% | — | -1304.8% |
| Income Tax Expense | 114K | (747K) | (25.06M) | 2.84M | 1.82M |
| Net Income | (381.9M) | (216.21M) | (151.09M) | (235.76M) | (197.53M) |
| Net Margin | — | — | -2204.7% | — | -1316.9% |
| EPS (Basic) | (4.24) | (2.31) | (1.57) | (2.06) | (1.46) |
| EPS (Diluted) | (4.24) | (2.31) | (1.57) | (2.06) | (1.46) |
| Weighted Avg Shares | 89.99M | 93.4M | 96.18M | 114.47M | 135.72M |
| Weighted Avg Shares (Diluted) | 89.99M | 93.4M | 96.18M | 114.47M | 135.72M |
Centessa Pharmaceuticals plc
NASDAQ:CNTA
Intrinsic Alpha fair value
Locked
Current Price
$40.50
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.